Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide
Authors
Keywords
Valproic acid, HDAC, Histone deacetylase inhibitor, Glioblastoma, Glioma, Low-grade, Survival, Progression
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 127, Issue 3, Pages 505-514
Publisher
Springer Nature
Online
2016-02-02
DOI
10.1007/s11060-016-2054-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic Decision Making in Patients with Newly Diagnosed Low Grade Glioma
- (2014) Adesh Tandon et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011
- (2014) Q. T. Ostrom et al. NEURO-ONCOLOGY
- Evolution of Malignant Glioma Treatment
- (2014) Richard Lee Price et al. NEUROSURGERY
- A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance
- (2013) F. Santoro et al. BLOOD
- Valproic Acid Use During Radiation Therapy for Glioblastoma Associated With Improved Survival
- (2013) Christopher A. Barker et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme
- (2013) M. Kerkhof et al. NEURO-ONCOLOGY
- Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
- (2012) Gregory Cairncross et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
- (2012) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme
- (2012) Greg D. Guthrie et al. JOURNAL OF NEUROSURGERY
- Primary brain tumours in adults
- (2012) Damien Ricard et al. LANCET
- Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
- (2012) Annika Malmström et al. LANCET ONCOLOGY
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
- (2012) Wolfgang Wick et al. LANCET ONCOLOGY
- French Brain Tumor DataBase: 5-Year Histological Results on 25 756 Cases
- (2011) Valérie Rigau et al. BRAIN PATHOLOGY
- Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation
- (2011) Krista A. Van Nifterik et al. JOURNAL OF NEURO-ONCOLOGY
- Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
- (2011) M. Weller et al. NEUROLOGY
- Potential Role for Valproate in the Treatment of High-Risk Brain Tumors of Childhood—Results from a Retrospective Observational Cohort Study
- (2011) Francisco Helder Cavalcante Felix et al. PEDIATRIC HEMATOLOGY AND ONCOLOGY
- Management of Low-Grade Glioma
- (2010) Nader Pouratian et al. Current Neurology and Neuroscience Reports
- Enhancement of Radiation Response in Osteosarcoma and Rhabomyosarcoma Cell Lines by Histone Deacetylase Inhibition
- (2010) Claudia Blattmann et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Oligodendrogliomas: Molecular Biology and Treatment
- (2009) J. E. C. Bromberg et al. ONCOLOGIST
- Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas
- (2008) Agda KB Lucio-Eterovic et al. BMC CANCER
- Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors
- (2008) Alfonso Duenas-Gonzalez et al. CANCER TREATMENT REVIEWS
- Postradiation Sensitization of the Histone Deacetylase Inhibitor Valproic Acid
- (2008) P. Chinnaiyan et al. CLINICAL CANCER RESEARCH
- Genomic changes in progression of low-grade gliomas
- (2008) Ahmed Idbaih et al. JOURNAL OF NEURO-ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More